Biomarkers for Oncology
JH · Effective Oct 1, 2015
133 active Medicare policies list C79.51, and 8 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 133
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
8 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C79.51 |
|---|---|---|
| Back Pain - Invasive Procedures | Mar 13, 2024 | Covered |
| Bone Growth Stimulators | May 30, 2023 | Covered |
| Brachytherapy | Jun 6, 2023 | Covered |
| Strontium Chloride Sr-89 | Dec 15, 2023 | Covered |
| Policy | Effective | Status of C79.51 |
|---|---|---|
| Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver |
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Jul 15, 2026
JK · Effective Jul 15, 2026
JJ · Effective Jul 24, 2022
JM · Effective Jul 24, 2022
J15 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Oct 1, 2015
JE · Effective Jul 5, 2016
JF · Effective Jul 5, 2016
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Jul 25, 2021
JE · Effective Jul 4, 2021
JF · Effective Jul 4, 2021
J5 · Effective Jul 25, 2021
J8 · Effective Jul 25, 2021
JJ · Effective Jul 25, 2021
JM · Effective Jul 25, 2021
JE · Effective Oct 8, 2018
JF · Effective Oct 8, 2018
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J15 · Effective Nov 18, 2019
JJ · Effective Nov 28, 2021
JM · Effective Nov 28, 2021
J5 · Effective Dec 16, 2019
J8 · Effective Dec 16, 2019
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
JJ · Effective Dec 3, 2023
JM · Effective Dec 3, 2023
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
J6 · Effective Jul 1, 2026
JL · Effective Apr 24, 2025
J5 · Effective Jan 1, 2026
National · Effective Dec 4, 2025
National · Effective Oct 1, 2025
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Jul 1, 2026
National · Effective Oct 1, 2026
National · Effective Jul 15, 2026
National · Effective Sep 27, 2026
National · Effective Mar 5, 2026
J6 · Effective Oct 1, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Apr 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2024
National · Effective Oct 1, 2024
| Oct 1, 2026 |
| Covered |
| Prostate Specific Antigen Testing | Apr 15, 2026 | Covered |
|---|
| Ultrasound Ablation for Oncologic Indications | Jan 6, 2026 | Covered |
|---|
| Policy | Effective | Status of C79.51 |
|---|---|---|
| Denosumab | Oct 1, 2026 | Covered |